CAMBRIDGE INNOVATION CAPITAL
MICROBIOTICA
CIC has been a great partner! In particular, I have really appreciated the personal touch. This has been a new area for me, and I have valued the opportunity to talk through the process about what to expect as an academic starting a new business and to talk through the challenges and pitfalls with someone that I trust. CIC has been with us through the good and the bad and I have really valued their support.
Q
WHAT IS YOUR VISION? WHAT IS THE PROBLEM YOU ARE TRYING TO SOLVE?
Q
WHAT IS UNIQUE ABOUT YOUR PRODUCT/TECHNOLOGY?
A
Our goal from the very beginning of setting up Microbiotica has been to make medicines out of poop that can improve health and cure disease. In the early days of my academic research, we saw clear potential in infectious diseases but as time has gone on the vision for potential benefit has continually expanded. Microbiotica’s lead programs in inflammatory bowel disease and improving response to immuno-oncology treatments are just two examples of how we believe defined bacteriotherapies have the potential to treat a wide range of conditions.
A
It was more bringing together a collection of skills and technologies that together optimises our understanding of the microbiome and how to influence it positively. My group at the Sanger Institute had particular insights around genomic sequencing, culturing, developing disease-specific algorithms and bioinformatics. Bringing these things together with a clear goal of developing novel medicines, we believe, gives us a differentiated offering.
DR TREVOR LAWLEY CSO AND CO-FOUNDER
26
